Could a cholesterol drug boost lung cancer treatment before surgery?
NCT ID NCT06385262
First seen Mar 06, 2026 · Last updated May 21, 2026 · Updated 8 times
Summary
This study tests whether adding the cholesterol-lowering drug alirocumab to standard chemotherapy and immunotherapy (cemiplimab) before surgery can help eliminate more cancer cells in people with early-stage non-small cell lung cancer (stages 1B-3A). About 126 adults will be randomly assigned to receive either the standard treatment or the standard plus alirocumab for three cycles before their tumor is removed. The main goal is to see if the combination leads to a complete disappearance of cancer in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Duke University
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.